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Introduction
Tumors of the small bowel are rare. The small bowel accounts
for 75% of the length and over 90% of the mucosal surface of
the gastrointestinal tract; however, small bowel cancers repre-
sent only 1% to 3% of all primary gastrointestinal malignancies
[1–3]. The clinical presentation of small bowel cancers is non-
specific with diarrhoea, abdominal pain, bleeding, extraintest-
inal symptoms (such as paraneoplastic phenomena) or acute
small bowel obstruction [4]. Diagnosis of small bowel tumors
is often delayed [5, 6], partly due to the fact that they are usual-
ly asymptomatic at the early stage [7] and there is low clinical
suspicion. By the time a diagnosis is reached, approximately
50% of small bowel cancers have already metastasised [8].
Nowadays, capsule endoscopy (CE) is a widely-accessible
and minimally invasive mode for diagnostic investigation of
the small bowel [9]. CE also gives detailed and panoramic views
of the entire small bowel, therefore it is suitable as first line in
the diagnostic workup of small bowel tumors. Since its intro-
duction into clinical practice, the literature on small bowel can-
cer diagnosis by CE remains limited [10]. This study aims to de-
scribe the frequency, indications and diagnostic work-up of pa-
tients with small bowel malignancy found by CE at a tertiary re-
ferral center in Scotland for small bowel capsule endoscopy
(SBCE).
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ABSTRACT
Background and study aims Small bowel cancer is rare,
accounting for < 5% of all gastrointestinal neoplasms. Cap-
sule endoscopy has become the procedure of choice for
non-invasive diagnosis of small bowel diseases. Data on
capsule endoscopy diagnosis of small bowel cancer are lim-
ited. The objective of the study was to determine the fre-
quency, indications and diagnostic work-up of patients
with small bowel malignancy found by capsule endoscopy
at a Scottish tertiary center.
Patients and methods In this retrospective study, records
all patients who underwent small bowel capsule endoscopy
at our center over a 10-year period were reviewed for possi-
ble malignancy. Further data were gathered on preceding
and subsequent investigations, management and outcome
of these patients.
Results From 1949 studies, small bowel malignancies were
diagnosed in only 7 patients (0.36%; 2F/5M; median age
50, range 34–67). The main indication was iron-deficiency
anemia (n =5). Prior to capsule endoscopy, 6 of 7 patients
had bidirectional endoscopies and one had gastroscopy. All
prior investigations were normal or nondiagnostic. Two of 7
experienced capsule retention. Five of 7 underwent sur-
gery. Four patients died, giving a 5-year survival rate of
42.9%.
Conclusion Small bowel malignancies diagnosed by cap-
sule endoscopy are rare, and the median age of 50 indicates
they are more common in relatively younger patients. Cap-
sule endoscopy is effective at diagnosing a rare malignancy
when other imaging modalities have failed.
Original article
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Patients and methods
This retrospective study involved all patients who underwent
SBCE between March 2005 and October 2015at the Centre for
Liver and Digestive Disorders, Royal Infirmary of Edinburgh,
Scotland. Patients excluded from CE were those with known
small bowel obstruction, implanted cardiac pacemakers and/
or pregnancy. Patients with risk factors for capsule retention,
such as those with a high probability of small bowel stenotic le-
sion or known small bowel inflammation (e. g. Crohn’s disease)
underwent CE provided there were no obstructive symptoms.
The standard protocol for performing CE involved a 12-hour
fast before the procedure, with intake of 2 liters of bowel prep-
aration solution (polyethylene glycol (PEG) before 2013, and
sodium picosulphate from 2013). Patients underwent CE using
one of two capsule models; either PillCamTM SB (Medtronic,
USA) or MiroCamTM (IntroMedic, Seoul, Korea). At our center,
all CEs are reported by at least 1 of 3 experienced CE readers
(experience with >100 CEs before the start of this study).
The data were collected from a prospectively-designed data-
base of all patients undergoing SBCE at our center. Patient
notes from the centralized patient management platform for
our healthcare trust were searched to determine those in
whom a small bowel malignancy was confirmed. Further data
were then gathered on previous and subsequent diagnostic in-
vestigations, management and outcome for these patients.
Data gathered: age, gender, indication for SBCE, SBCE find-
ings, cross-sectional/radiological imaging both before and after
SBCE, subsequent clinical outcomes. Iron deficiency anemia
(IDA) was defined as per World Health Organisation guidelines:
Hb <13g/dL in males or < 12g/dL in females, with evidence of
iron deficiency (MCV<80 fL or ferritin < 12–15µg/L).
A literature review of the databases PubMed and Embase
was also conducted for publications reporting the epidemiolo-
gy of small bowel tumors. This was carried out via a focused
search using the terms “small bowel tumors” and “small bowel
malignancy” as keywords. Relevant studies were included if
they reported the incidence of small bowel tumors in their co-
horts.
Results
The total number of SBCE studies carried out between 2005 and
2015 was 1949; 1082 performed with PillCamTMSB and 867
using MiroCamTM. Small bowel malignancy was confirmed in 7
patients (0.36%; 5 male/2 female). The median age was 50
years (range 34–67). There were 2 lymphomas, 2 gastrointes-
tinal stromal tumors (GISTs), 2 duodenal adenocarcinomas and
1 jejunal metastasis from a sarcoma of the lung. In this sub-
group, indications for CE were IDA (iron-deficiency anemia)
(n =5), unexplained diarrhoea (n=1) and clinical suspicion of
lymphoma (n=1). The median time from first symptom to di-
agnosis in our patients was 12 months (range 2–18). All pa-
tients with a small bowel malignancy had other investigations
carried out prior to SBCE. Six of 7 had prior negative bidirec-
tional gastrointestinal endoscopy. In 2 patients, SBCE was car-
ried out immediately following negative UGIE and colonosco-
py. One patient had a normal upper gastrointestinal endos-
copy (UGIE) with no colonoscopy carried out. Other prior in-
vestigations before SBCE included: abdominal ultrasound scan
(USS) (n=2), computed tomography (CT) imaging of the
chest, abdomen and/or pelvis (n =4), small bowel barium fol-
low-through (n =1) and bone marrow aspirate (n=1). The
mean number of diagnostic procedures per patient, before
CE, was 3. All prior diagnostic procedures were normal or non-
diagnostic. Two of the 7 patients experienced asymptomatic
capsule retention. Both these patients had duodenal adeno-
carcinomas; 1 required capsule removal by push enteroscopy
and the other by UGIE.
All 7 patients had further investigations following CE. Six had
a CT scan of their chest, abdomen, and pelvis carried out for
staging. Two patients had push enteroscopy (PE), both of
whom had a diagnosis of duodenal adenocarcinoma. One had
double balloon enteroscopy (DBE), 2 had colonoscopy, 2 had
UGIE; and there was 1 bone marrow aspiration. All patients
had histological confirmation of malignancy. The SBCE findings
(and subsequent investigations) led to a change in manage-
ment in all our patients diagnosed with a small bowel malignan-
cy. Three subjects had a small bowel resection. One patient
with a GIST was also administered Imatinib following resection.
Of the 2 individuals with a duodenal adenocarcinoma, 1 under-
went a gastroenterostomy and 1 had an elective Whipple pro-
cedure. Four patients died within 1 year of their diagnosis, 2 of
whom died after surgery and the other 2 before their planned
surgery. Of the 3 surviving patients at the time of writing, 2
are being followed up by the oncology team and one by the gas-
troenterology team. ▶Table 1 summarizes the findings.
Discussion
Introduction of wireless CE into clinical practice has radically
changed diagnostic algorithms for small bowel pathology [9,
11]. However, there is a growing body of evidence suggesting
a high miss rate for sinister small bowel pathology using CE
[12–15]. Radiological modalities, such as small bowel follow-
through, enteroclysis and cross-sectional imaging (CT and
magnetic resonance imaging), permit detection of lesions in
the whole small bowel but provide inadequate detail of the
bowel lumen and mucosa [16]. In our cohort, our patients un-
derwent a similar number of investigations preceding SBCE
compared to other studies (range 3.19–4.6) (See ▶Table2 for
a comparison of previous studies on SB malignancy diagnosed
by CE) [17–43].
The reported rate of small bowel malignancy diagnosis by CE
varies. Our cohort has a very low reported frequency of small
bowel malignancy diagnosis at 0.36%. Our results are consis-
tent with other published studies on the detection of SB malig-
nancies by CE, detailed in ▶Table 2. Notably, in a large multi-
center study by Rondonotti et al with 5129 CEs from 29 centers
in 10 European countries, the authors observed a significant in-
verse correlation between the frequency of tumors diagnosed
and the number of CE examinations performed at a particular
center [10]. In contrast, this single-center study originated at a
tertiary hospital serving a large but relatively homogeneous
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population from southeast Scotland. Furthermore, the lower in-
cidence of small bowel malignancy found on CE in our group
may also, to some extent, be an artifact of less stringent local
CE referral policies due to the accessibility of the CE service.
This is reflected by the overall high proportion of normal CEs
(971/1949; 49.8%). A significant 51.0% (994/1949) of our re-
ferrals were for obscure gastrointestinal bleeding and 41.3%
(805 /1949) specifically for IDA; the low diagnostic yield is in
line with that of previous published studies and systematic re-
views on CE in patients with IDA [44].
With 1949CE reports, our study represents one of the lar-
gest single-center studies to date reporting on small bowel ma-
lignancies. ▶Fig.1 shows the forest plot for the rate of small
bowel tumors detected by CE in the studies from ▶Table 2:
using the random effects model (DerSimonian-Laird) due to
high study heterogeneity, the overall proportion of small bowel
tumors diagnosed on CE was 0.05 (95%CI 0.04–0.06), i. e. 5%.
When only malignant tumors (if specified by the respective
studies) were taken into account, the rate of diagnosis via CE
was 0.03 (95%CI 0.02–0.04), or 3%, ▶Fig. 2.
▶ Table 1 Case-based demographics, clinical findings, investigations, management, and outcomes in 7 Patients with small bowel tumor diagnosis
Patient
Number
Indica-
tion
Time from
presenta-
tion to
diagnosis
Diagnosis and
CE appearances
Previous In-
vestigations
Subsequent
Investiga-
tions
Mode used to
confirm diag-
nosis and find-
ings
Manage-
ment
Outcome
1 IDA 2 months Duodenal ade-
nocarcinoma:
Stricturing,
nodular mucosa,
CE retained
Abdominal
USS, UGIE,
colonoscopy
UGIE, PE,
CT CAP
UGIE:
Tumor in duo-
denum and re-
tained CE
Gastroenter-
ostomy and
palliative
care
Deceased
2 IDA 18 months GIST (right iliac
fossa):
Mucosal bulge
CT, UGIE,
colonoscopy
CT CAP CT CAP:
Soft tissue no-
dules with flecks
of calcification
Small bowel
resection
GI follow-
up
3 IDA 2 months Jejunal metas-
tasis from sarco-
ma of lung:
Multiple infiltra-
tive lesions
CT chest,
BMA, UGIE
DBE, CT CAP DBE:
Area of intussus-
ception with
jejunal lesions
Small bowel
resection
and pallia-
tive care
Deceased
4 Possible
lym-
phoma
11 months Lymphoma
(diffuse):
Extensive pseu-
dopolyp forma-
tion at terminal
ileum
Small bowel
follow
through,
UGIE, colo-
noscopy, CT
CAP
Colonos-
copy
Colonoscopy:
Extensive pseu-
dopolyp forma-
tion
Planned
surgery
Deceased
(3 months
after
diagnosis)
5 IDA 13 months Duodenal ade-
nocarcinoma:
Capacious
duodenum, ob-
structing lesion
with infiltrative
characteristics
in proximal jeju-
num, CE retained
UGIE, colo-
noscopy, ab-
dominal USS,
CT
PE, CT CAP PE:
Tumor in duo-
denum and re-
tained CE
Elective
Whipple
procedure
Oncology
follow-up
6 IDA 16 months GIST (jejunal):
Mucosal bulge
UGIE, colo-
noscopy
CT CAP CT CAP:
Area of mucosal
thickening and
inflammatory
changes at duo-
denal-jejunal
junction, reac-
tive lymph nodes
Small bowel
resection
and imatinib
Oncology
follow-up
7 Diar-
rhoea
unknown Lymphoma
(diffuse):
Infiltrative
appearances
UGIE, colo-
noscopy
UGIE, colo-
noscopy, CT
CAP, BMA
UGIE:
Severe rugal
hyperplasia
Planned
surgery
Deceased
(2 months
after
diagnosis)
BMA, bone marrow aspiration; CE, capsule endoscopy; CT CAP, computed tomography of chest, abdomen and pelvis; IDA, iron deficiency anaemia; PE, push en-
teroscopy; UGIE, upper gastrointestinal endoscopy; USS, ultrasound scan
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The most common indication for CE in our study was IDA
(71.4%). This matches the published reports on small bowel
cancers diagnosed through CE, where IDA accounted for 60%
to 100% of indications. In our group, malignancy was diag-
nosed more frequently in younger patients (≤55y) with IDA (3
of 312CE cases, 0.96%) compared with those older than age 55
years (2 of 682CE cases, 0.29%). Our findings highlight the im-
portance of keeping small bowel malignancy on the differential
diagnosis in younger patients with IDA [44, 45].
Early detection of small bowel malignancy has a positive im-
pact on survival. Overall, the prognosis of small bowel tumors
remains poor [46–48] and a diagnostic delay of up to 1.5 years
has been estimated for malignant small bowel tumors. Features
of small bowel tumors contributing to delayed diagnosis in-
clude their slow, extraluminal growth and lack of specific symp-
toms [10].
The major limitations of this observational study are its ret-
rospective design and the fact that information on follow-up
was only available for a limited number of patients in our co-
hort. This was due to the large catchment area of our tertiary
referral center, which meant that a significant proportion of pa-
tients were returned to the care of their referring centers fol-
lowing CE. However, it still represents one of the largest studies
to date on small bowel cancers diagnosed by CE.
Conclusion
In summary, in our tertiary care center, the rate of diagnosis of
small bowel malignancies via CE was 0.36%. This was a low di-
agnostic yield in comparison to other studies, but possibly a
truer figure given our large sample size from a single center.
Younger patients referred for CE with IDA were more likely to
be diagnosed with small bowel cancer. The mortality rate for
patients diagnosed this way was high, with a 5-year survival
rate of only 42.9%. The potential diagnostic superiority of CE
over other small bowel investigations and the resultant change
in management plans suggest that CE is an invaluable third-line
diagnostic procedure following negative bidirectional gastroin-
testinal endoscopy when other imaging modalities have failed.
Caunedo et al 2004 0.07 (0.03, 0.14)
Delvaux et al 2004 0.23 (0.11, 0.38)
Rastogi et al 2004 0.02 (0.00059, 0.12)
Carlo et al 2005 0.06 (0.04, 0.08)
Teramoto et al 2005 0.04 (0.0054, 0.15)
Bailey et al 2006 0.06 (0.04, 0.09)
Cobrin et al 2006 0.06 (0.04, 0.09)
Urbain et al 2006 0.02 (0.01, 0.04)
van Tuyl et al 2006 0.03 (0.01, 0.06)
Baichi et al 2007 0.03 (0.01, 0.06)
Estévez et al 2007 0.07 (0.05, 0.11)
Rondonotti et al 2008 0.02 (0.02, 0.03)
Spada et al 2008 0.03 (0.02, 0.06)
Ersoy et al 2009 0.06 (0.02, 0.15)
Ren et al 2009 0.06 (0.03, 0.11)
Cheung et al 2010 0.04 (0.03, 0.06)
Sanhueza et al 2010 0.04 (0.0091, 0.12)
Sîngeap et al 2010 0.05 (0.02, 0.11)
Trifan et al 2010 0.05 (0.02, 0.11)
Sidhu et al 2011 0.02 (0.0096, 0.02)
Achour et al 2012 0.14 (0.07, 0.22)
Urgesi et al 2012 0.04 (0.02, 0.06)
Zhang et al 2012 0.15 (0.12, 0.19)
Pongprasopchai et al 2013 0.07 (0.03, 0.14)
Zagorowicz et al 2013 0.10 (0.06, 0.16)
Yang et al 2014 0.0082 (0.001, 0.03)
Calabrese et al 2015 0.06 (0.05, 0.08)
Moneghini et al 2016 0.03 (0.02, 0.04)
Johnston et al 2016 0.0036 (0.0014, 0.0074)
combined 0.05 (0.04, 0.06)
Proportion (95 % confi dence interval)
Cochran Q = 356.301055 (df = 28) P < 0.0001
Moment-based estimate of between studies variance = 0.022223
I2 (inconsistency) = 92.1 % (95 % Cl = 90.2 % to 93.5 %)
0.40.0 0.1 0.2 0.3
▶ Fig. 1 Forest plot showing pooled rate of diagnosis of small bowel tumors by CE.
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